ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 057,80
-0,92%
Dow Jones
38 852,86
-0,55%
DAX
18 677,87
-0,45%
Brent Oil
84,245
-0,09%
Bitcoin
68 410,43
0,17%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Pharming Group NV (PHAR)

  7. Pharming Group NV (PHAR) Actualités

PHAR

Pharming Group NV (PHAR)

Pharming Group NV
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PHAR
DateHeureSourceTitreSymboleSociété
21/05/202419h54Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHARPharming Group NV
24/08/202308h00PR Newswire (US)Pharming Group to participate in September investor conferencesNASDAQ:PHARPharming Group NV
14/08/202307h00PR Newswire (US)Pharming Group to convene Extraordinary General Meeting of ShareholdersNASDAQ:PHARPharming Group NV
09/08/202307h00PR Newswire (US)Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in JapanNASDAQ:PHARPharming Group NV
03/08/202307h00PR Newswire (US)Pharming Group reports second quarter and first half 2023 financial resultsNASDAQ:PHARPharming Group NV
18/07/202307h00PR Newswire (US)Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the BoardNASDAQ:PHARPharming Group NV
13/07/202308h00PR Newswire (US)Pharming Group to report second quarter and first half 2023 financial results on August 3NASDAQ:PHARPharming Group NV
01/06/202312h15Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:PHARPharming Group NV
01/06/202307h00PR Newswire (US)Pharming announces sale of priority review voucherNASDAQ:PHARPharming Group NV
25/05/202308h00PR Newswire (US)Pharming Group to attend the following Investor Conferences in JuneNASDAQ:PHARPharming Group NV
17/05/202317h28PR Newswire (US)Pharming Group reports on results of the 2023 Annual General Meeting of ShareholdersNASDAQ:PHARPharming Group NV
11/05/202307h00PR Newswire (US)Pharming Group reports financial results for the first quarter of 2023NASDAQ:PHARPharming Group NV
26/04/202308h00PR Newswire (US)Pharming to attend the H.C. Wainwright BioConnect Investor Conference 2023NASDAQ:PHARPharming Group NV
19/04/202308h00PR Newswire (US)Pharming to attend the Van Lanschot Kempen Life Sciences Conference 2023NASDAQ:PHARPharming Group NV
19/04/202307h36PR Newswire (US)Notice of First Quarter 2023 ResultsNASDAQ:PHARPharming Group NV
13/04/202313h11PR Newswire (US)Pharming to present at the 22nd Annual Needham Virtual Healthcare Conference 2023NASDAQ:PHARPharming Group NV
11/04/202307h00PR Newswire (US)Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.NASDAQ:PHARPharming Group NV
05/04/202312h57Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:PHARPharming Group NV
05/04/202308h00PR Newswire (US)Pharming Group convenes the Annual General Meeting of Shareholders 2023NASDAQ:PHARPharming Group NV
05/04/202307h00PR Newswire (US)Pharming Group announces the filing of its 2022 Annual Report and Form 20-FNASDAQ:PHARPharming Group NV
30/03/202316h39PR Newswire (US)Pharming to present at the Guggenheim Healthcare Talks - Genomic Medicines and Rare Disease DaysNASDAQ:PHARPharming Group NV
25/03/202300h22Dow Jones NewsADRs End Mostly Lower, Pharming Group Trades ActivelyNASDAQ:PHARPharming Group NV
24/03/202319h35PR Newswire (US)Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDSNASDAQ:PHARPharming Group NV
13/03/202310h43PR Newswire (US)Pharming Group announces that it expects to have full access today to its cash on deposit at Silicon Valley Bank Limited in light of UK Government announcementNASDAQ:PHARPharming Group NV
13/03/202309h34Dow Jones NewsPharming Expects to Have Access to $26 Million It Has on Deposit at SVB USNASDAQ:PHARPharming Group NV
13/03/202308h15PR Newswire (US)Pharming Group announces that it expects to have full access today to its cash on deposit at Silicon Valley Bank in light of US Government announcementNASDAQ:PHARPharming Group NV
12/03/202319h30PR Newswire (US)Pharming Group issues statement regarding the events surrounding Silicon Valley BankNASDAQ:PHARPharming Group NV
28/02/202307h00PR Newswire (US)Notice of Full Year 2022 financial resultsNASDAQ:PHARPharming Group NV
21/02/202307h00PR Newswire (US)Pharming announces first patient enrolled in pediatric clinical trial of leniolisibNASDAQ:PHARPharming Group NV
16/02/202307h00PR Newswire (Canada)Pharming provides update on EMA regulatory review of leniolisib for APDS in EuropeNASDAQ:PHARPharming Group NV
 Showing the most relevant articles for your search:NASDAQ:PHAR

Dernières Valeurs Consultées

BOV
RADL3R
RAIA DROGASIL ON
BOV
ALPA3M
ALPARGATAS ON
EU
SNCH
SNCF 2.303% 11jul2067
NYSE
TOT
TOTAL
TSXV
PPY.A
BOV
RCSL4
RECRUSUL PN
LSE
LRE
Lancashire
EU
J625S
J625S
EU
L224S
L224S
BOV
SIMH3
Simpar ON
BOV
SCAR3
SÃO CARLOS ON
EU
ECMPA
Eurocommercial Property NV
EU
ALWF
Winfarm
BOV
NEMO3
SUZANO HOLD ON
EU
SNC
Sonaecom Sgps
BOV
SCAR3M
SÃO CARLOS ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés